Management of coagulation abnormalities in liver disease

References

• Lisman T, Leebeek FW, de Groot PG. Haemostatic abnormalities. in patients with liver disease. J Hepatol 2002;37(2):280-7
   PubMed Web of Science ®Google Scholar
• Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010;116(6):878-85
   PubMed Web of Science ®Google Scholar
• Lisman T, Bakhtiari K, Pereboom IT, et al. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010;52(3):355-61
   PubMed Web of Science ®Google Scholar
• Massicotte L, Denault AY, Beaulieu D, et al. Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center. Transplantation 2012;93(12):1276-81
   PubMed Web of Science ®Google Scholar
• Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep 2004;3(5):324-30
   PubMedGoogle Scholar
• Dzik W, Rao A. Why do physicians request fresh frozen plasma? Transfusion 2004;44(9):1393-4
   PubMed Web of Science ®Google Scholar
• Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010;53(2):362-71
   PubMed Web of Science ®Google Scholar
• Northup PG, Sundaram V, Fallon MB, et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2008;6(1):2-9
   PubMed Web of Science ®Google Scholar
• Tripodi A, Anstee QM, Sogaard KK, et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011;9(9):1713-23
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006;44(4):1039-46
   PubMed Web of Science ®Google Scholar
• Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007;24(4):250-8
   PubMed Web of Science ®Google Scholar
• Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006;101(7):1524-8. quiz 1680
   PubMed Web of Science ®Google Scholar
• Caldwell S, Shah N. The prothrombin time-derived international normalized ratio: great for Warfarin, fair for prognosis and bad for liver-bleeding risk. Liver Int 2008;28(10):1325-7
   PubMed Web of Science ®Google Scholar
• Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol 2013;11(9):1064-74
   PubMed Web of Science ®Google Scholar
• Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966;45(5):645-57
   PubMed Web of Science ®Google Scholar
• Kajihara M, Kato S, Okazaki Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003;37(6):1267-76
   PubMed Web of Science ®Google Scholar
• Goulis J, Chau TN, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999;44(5):754-8
   PubMed Web of Science ®Google Scholar
• Ikura Y, Ohsawa M, Okada M, et al. The significance of platelet consumption in the development of thrombocytopenia in patients with cirrhosis. Am J Med Sci 2013;346(3):199-203
   PubMed Web of Science ®Google Scholar
• Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44(1):53-61
   PubMed Web of Science ®Google Scholar
• La Mura V, Reverter JC, Flores-Arroyo A, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011;60(8):1133-8
   PubMed Web of Science ®Google Scholar
• Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012;56(4):1439-47
   PubMed Web of Science ®Google Scholar
• Lisman T, Adelmeijer J, de Groot PG, et al. No evidence for an intrinsic platelet defect in patients with liver cirrhosis--studies under flow conditions. J Thromb Haemost 2006;4(9):2070-2
   PubMed Web of Science ®Google Scholar
• Basili S, Raparelli V, Riggio O, et al. NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. Liver Int 2011;31(10):1533-40
   PubMed Web of Science ®Google Scholar
• Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137(6):2105-11
   PubMed Web of Science ®Google Scholar
• Hollestelle MJ, Geertzen HG, Straatsburg IH, et al. Factor VIII expression in liver disease. Thromb Haemost 2004;91(2):267-75
   PubMed Web of Science ®Google Scholar
• Hollestelle MJ, Poyck PP, Hollestelle JM, et al. Extra-hepatic factor VIII expression in porcine fulminant hepatic failure. J Thromb Haemost 2005;3(10):2274-80
   PubMed Web of Science ®Google Scholar
• Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983;61(6):1196-202
   PubMed Web of Science ®Google Scholar
• Castoldi E, Simioni P, Tormene D, et al. Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost 2010;8(2):294-300
   PubMed Web of Science ®Google Scholar
• Potze W, Arshad F, Adelmeijer J, et al. Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels. Br J Haematol 2013;162(6):819-26
   PubMed Web of Science ®Google Scholar
• Tripodi A, Primignani M, Lemma L, et al. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 2013;59(2):265-70
   PubMed Web of Science ®Google Scholar
• Tripodi A, Primignani M, Lemma L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010;52(1):249-55
   PubMed Web of Science ®Google Scholar
• Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001;121(1):131-9
   PubMed Web of Science ®Google Scholar
• Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982;99(2):217-30
   PubMed Web of Science ®Google Scholar
• Pernambuco JR, Langley PG, Hughes RD, et al. Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 1993;18(6):1350-6
   PubMed Web of Science ®Google Scholar
• Leebeek FW, Kluft C, Knot EA, et al. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991;101(5):1382-90
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999;94(8):2569-74
   PubMed Web of Science ®Google Scholar
• Thalheimer U, Triantos CK, Samonakis DN, et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005;54(4):556-63
   PubMed Web of Science ®Google Scholar
• van der Poll T, Buller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322(23):1622-7
   PubMed Web of Science ®Google Scholar
• Logan TF, Virji MA, Gooding WE, et al. The pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1994;271(6):427-8
   PubMed Web of Science ®Google Scholar
• Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101(10):3765-77
   PubMed Web of Science ®Google Scholar
• Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29(6):1655-61
   PubMed Web of Science ®Google Scholar
• Mucino-Bermejo J, Carrillo-Esper R, Uribe M, Mendez-Sanchez N. Coagulation abnormalities in the cirrhotic patient. Ann Hepatol 2013;12(5):713-24
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362(9):823-32
   PubMed Web of Science ®Google Scholar
• Turon F, Casu S, Hernandez-Gea V, Garcia-Pagan JC. Variceal and other portal hypertension related bleeding. Best Pract Res Clin Gastroenterol 2013;27(5):649-64
   PubMed Web of Science ®Google Scholar
• Villa E, Camma C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143(5):1253-60. e1-4
   PubMed Web of Science ®Google Scholar
• Shah NL, Northup PG, Caldwell SH. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Ann Hepatol 2012;11(5):686-90
   PubMed Web of Science ®Google Scholar
• Targher G, Chonchol M, Miele L, et al. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009;35(3):277-87
   PubMed Web of Science ®Google Scholar
• Caldwell S, Northup PG. Bleeding complication with liver biopsy: is it predictable? Clin Gastroenterol Hepatol 2010;8(10):826-9
   PubMed Web of Science ®Google Scholar
• Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005;41(3):553-8
   PubMed Web of Science ®Google Scholar
• Gatt A, Riddell A, Calvaruso V, et al. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010;8(9):1994-2000
   PubMed Web of Science ®Google Scholar
• Lisman T, Bakhtiari K, Adelmeijer J, et al. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost 2012;10(7):1312-19
   PubMed Web of Science ®Google Scholar
• Munoz SJ, Rajender Reddy K, Lee W; Acute Liver Failure Study Group. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008;9(1):103-7
   PubMed Web of Science ®Google Scholar
• Stravitz RT, Kramer AH, Davern T, et al. Acute Liver Failure Study Group. Intensive care of patients with acute liver failure: recommendations of the U.S. Crit Care Med 2007;35(11):2498-508
   PubMed Web of Science ®Google Scholar
• Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986;6(1):79-86
   PubMed Web of Science ®Google Scholar
• Hron G, Kollars M, Binder BR, et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006;296(4):397-402
   PubMed Web of Science ®Google Scholar
• Besser M, Baglin C, Luddington R, et al. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008;6(10):1720-5
   PubMed Web of Science ®Google Scholar
• Tripodi A, Legnani C, Chantarangkul V, et al. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008;6(8):1327-33
   PubMed Web of Science ®Google Scholar
• van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008;142(6):889-903
   PubMed Web of Science ®Google Scholar
• Mallett SV, Chowdary P, Burroughs AK. Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver Int 2013;33(7):961-74
   PubMed Web of Science ®Google Scholar
• Stravitz RT. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol (N Y) 2012;8(8):513-20
   PubMedGoogle Scholar
• Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis 2001;12(5):327-37
   PubMed Web of Science ®Google Scholar
• Stanworth SJ, Hyde CJ, Murphy MF. Evidence for indications of fresh frozen plasma. Transfus Clin Biol 2007;14(6):551-6
   PubMed Web of Science ®Google Scholar
• Tinmouth A. Evidence for a rationale use of frozen plasma for the treatment and prevention of bleeding. Transfus Apher Sci 2012;46(3):293-8
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012;367(8):716-24
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126(1):11-28
   PubMed Web of Science ®Google Scholar
• Stanca CM, Montazem AH, Lawal A, et al. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg 2010;68(1):138-43
   PubMed Web of Science ®Google Scholar
• Youssef WI, Salazar F, Dasarathy S, et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003;98(6):1391-4
   PubMed Web of Science ®Google Scholar
• Patel IJ, Davidson JC, Nikolic B, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2012;23(6):727-36
   PubMed Web of Science ®Google Scholar
• Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010;8(10):899-902. quiz e109
   PubMed Web of Science ®Google Scholar
• Arshad F, Ickx B, van Beem RT, et al. Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. BMC Surg 2013;13:22
   PubMed Web of Science ®Google Scholar
• Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368(1):11-21
   PubMed Web of Science ®Google Scholar
• Burroughs AK, Matthews K, Qadiri M, et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 1985;291(6506):1377-81
   PubMed Web of Science ®Google Scholar
• Wong AY, Irwin MG, Hui TW, et al. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 2003;50(1):14-20
   PubMed Web of Science ®Google Scholar
• Pivalizza EG, Warters RD, Gebhard R. Desmopressin before liver transplantation. Can J Anaesth 2003;50(7):748-9
   PubMed Web of Science ®Google Scholar
• Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000;355(9212):1303-9
   PubMed Web of Science ®Google Scholar
• Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996;85(5):1043-8. discussion 30A-31A
   PubMed Web of Science ®Google Scholar
• Gurusamy KS, Pissanou T, Pikhart H, et al. Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev 2011(12):CD009052
   Google Scholar
• Ramsay MA. Con: antifibrinolytics are not safe and effective in patients undergoing liver transplantation. J Cardiothorac Vasc Anesth 2006;20(6):891-3
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Available from: www.clinicaltrials.gov/ct2/show/NCT01658124
   Google Scholar
• Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001;71(3):402-5
   PubMed Web of Science ®Google Scholar
• Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005;11(8):895-900
   PubMed Web of Science ®Google Scholar
• Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005;11(8):9739
   Web of Science ®Google Scholar
• Bendtsen F, D’Amico G, Rusch E, et al. Effect of recombinant factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials. J Hepatol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30(6):270-382
   PubMed Web of Science ®Google Scholar
• Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis - Possibilities and caveats. J Hepatol 2013;59(2):358-66
   PubMed Web of Science ®Google Scholar
• Garcia-Fuster MJ, Abdilla N, Fabia MJ, et al. Venous thromboembolism and liver cirrhosis. Rev Esp Enferm Dig 2008;100(5):259-62
   PubMed Web of Science ®Google Scholar
• Levi M, Hovingh GK, Cannegieter SC, et al. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008;111(9):4471-6
   PubMed Web of Science ®Google Scholar
• Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010;44(6):448-51
   PubMed Web of Science ®Google Scholar
• Intagliata N, Henry Z, Shah N, et al. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014;34(1):26-32
   PubMed Web of Science ®Google Scholar
• Potze W, Arshad F, Adelmeijer J, et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 2014;9(2):e88390
   Web of Science ®Google Scholar
• Senzolo M, Rodriguez-Castro KI, Rossetto V, et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012;10(9):1823-9
   PubMed Web of Science ®Google Scholar
• Bechmann LP, Sichau M, Wichert M, et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011;31(1):75-82
   PubMed Web of Science ®Google Scholar
• Lisman T, Porte RJ. Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver Int 2011;31(7):1063
   PubMed Web of Science ®Google Scholar
• Potze W, Arshad F, Adelmeijer J, et al. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol 2013;163(5):666-73
   PubMed Web of Science ®Google Scholar
• Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012;119(13):3016-23
   PubMed Web of Science ®Google Scholar
• Martinez M, Tandra A, Vuppalanchi R. Treatment of acute portal vein thrombosis by non-traditional anticoagulation. Hepatology 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Intagliata N, Maitland H, Northup P, Caldwell S. Treating thrombosis in cirrhosis patients with new oral agents: ready or not? Hepatology 2014. [Epub ahead of print]
   Google Scholar
• Feys HB, Canciani MT, Peyvandi F, et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007;138(4):534–40
   PubMed Web of Science ®Google Scholar
• Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008;15(5):473–80
   PubMed Web of Science ®Google Scholar
• Ordinas A, Escolar G, Cirera I, et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology 1996;24(5):1137–42
   PubMed Web of Science ®Google Scholar
• Laffi G, Cominelli F, Ruggiero M, et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988;8(6):1620–6
   PubMed Web of Science ®Google Scholar
• Laffi G, Marra F, Gresele P, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992;103(2):641–6
   PubMed Web of Science ®Google Scholar
• Desai K, Mistry P, Bagget C, et al. Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis. Lancet 1989;1(8640):693–5
   PubMed Web of Science ®Google Scholar
• Escolar G, Cases A, Vinas M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999;84(7):614–19
   PubMed Web of Science ®Google Scholar
• Lisman T, Porte RJ. Pitfalls in assessing platelet activation status in patients with liver disease. Liver Int 2012;32(6):1027. author reply 1028
   PubMed Web of Science ®Google Scholar
• Violi F, Ferro D, Basili S, et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. Hepatology 1993;17(1):78–83
   PubMed Web of Science ®Google Scholar
• Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003;38(1):230–7
   PubMed Web of Science ®Google Scholar
• Hu KQ, Yu AS, Tiyyagura L, et al. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001;96(5):1581–6
   PubMed Web of Science ®Google Scholar